BLTE
$161.41
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
Intraday
Recent News
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference
Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl outlined the company’s approach to treating Stargardt disease and reviewed top-line results from its Phase 3 DRAGON trial during a conference session hosted by Leerink analyst Marc Goodman. Stargardt disease: prevalence and unmet need Sc
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Belite Bio (BLTE) to $266 from $200 and keeps an Overweight rating on the shares. Recent commentary suggested a possibility of a much higher WAC than the $200K/year the firm was modeling, the analyst tells investors in a research note. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's pote
Belite Bio Advances Tinlarebant Toward FDA Review After DRAGON Success
Belite Bio reported positive topline data from its pivotal Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1. The company plans to submit a New Drug Application to the US FDA in Q2 2026 for tinlarebant. Belite Bio recently completed a public offering intended to support commercial preparations and further pipeline development. Belite Bio, listed as NasdaqCM:BLTE, is moving closer to a potential commercial launch with a first in class therapy for Stargardt...
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript
Hao-Yuan Chuang: Thank you for joining today's call to discuss our fourth quarter and full year 2025 financial results. Now moving to 2026, as I said, this will be a transformative year for Belite Bio, Inc.
Belite Bio Inc (BLTE) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
Belite Bio Inc (BLTE) reports significant progress in drug development and financial positioning, despite increased operational costs and net losses.